Teva Pharmaceutical Industries (TEVA) said Monday it plans to issue $2 billion equivalent of senior notes through its special purpose finance subsidiaries.
Teva Pharmaceutical Finance Netherlands II intends to offer euro-denominated notes, while Teva Pharmaceutical Finance Netherlands III and Teva Pharmaceutical Finance Netherlands IV aim to offer US dollar-denominated notes.
Separately, the company said it launched cash tender offers for up to $2 billion worth of certain series of notes. The offers are scheduled to expire at 5 pm ET June 17, unless extended or earlier terminated.
Teva said it expects to use the net proceeds from the planned notes issuance, along with cash on hand, to help fund the tender offers, among other things.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。